Semaglutide
GLP-1 receptor agonist with clinical studies of glucose control and weight.
Search names: Ozempic, Wegovy, Rybelsus
Evidence
Human · STEP 5
Describes the linked sources, not an overall score for product quality or effectiveness.Half-life
Statistics reference: About 1 week
Human information in catalogueContext and sources for the statistics reference
Human terminal half-life; about 168 hours.
About 1 week · Catalogue information from PeptideTracker.ai; read the limitation above. PeptideTracker.ai · Semaglutide ↗
Half-life, duration of effect and shelf life are different measures. Catalogue values may differ between variants and administration routes. Curves continue to use their stated statistics reference.
Adverse effects and limitations
Gastrointestinal adverse effects occur in the linked trials. See the specific source for study arm, frequency and other events.
Sources and further reading
Vital · user-supplied screen recordings, 1 Nov 2026
Study / medicine dataSemaglutide · STEP 5 trial↗Find researchPubMed · Semaglutide↗Research information, not a personal dosing plan. Last reviewed: 2026-11-01.